1Tosi P,Zamagni E,Cellini C,et al.Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma[J].Haematologica,2002,87:408.
2Dimopoulos M A,Hamilos G,Zomas A,et al.Pulsed cyclophosphamide,thalidomide and dexamethasone:an oral regimen for previously treated patients with multiple myeloma[J].Hematol J,2004,5:112.
3Mohamad A.Hussein.Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma[J].Oncologist,2002,7(Suppl1):20.
4Laroche M.Brousset P,Ludot I,et al.Increased vascularization in myeloma[J].Eur J Haematol,2001,66:89.
5Munshi N C.Arsenic trioxide:an emerging therapy for multiple myeloma[J].Oncologist,2001,6(Suppl2):17.
6Munshi N C,Tricot G,Desikan R,et al.Clinical activity of arsenic trioxide for the treatment of m ultiple myeloma[J].Leukemia,2002,16:1835.
7Bahlis N J,McCafferty Grad J,Jordan McMurry I,et al.Feasibility and correlates of arsenic trioxide combined with ascorbic acidmediated depletion of intracellular glutathione for the treatment of re1apsed/refractory multiple myeloma[J].Clin Cancer Res,2002,8:3658.
8Vacca A,Ribattti D,Presta M,et al.Bone marrow neovascularization plasma cell angiogenic potential and matrix metallpproteinase-2 secretion paragression of human multiple myeloma[J].Blood,1999,93:3064.
3Barlogie B, Zangari M, Spencer T, et al. Thalidomide in the management of multiple myeloma. Semin Hematol, 2001,38:250-259.
4Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med,1999,341:1565-1571.
5Rajkumar S V, Kyle R A. Angiogenesis in multiple myeloma. Semin Oncol, 2001,28:560-564.
6Kneller A, Raanani P, Hardan I,et al. Therapy with thalidomide in refractory multiple myeloma patientsthe revival of an old drug. Br J Haematol, 2000,108:391-393.
7Thompson M A,Witzig T E, Kumar S, et al. Plasma levels of tumor necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma. Br J Haematol,2003,123:305-308.
8Salles G, Bienvenu J, Bastion Y, et al. Elevated circu lating levels of TNFa and its p55 solube receptor are associated with an adverse prognosis in lymphoma patients. BrJ Haematol, 1996, 93: 352-359.
9Bark V. Nisman B, Polliack A, et al. The tumor necrosis factor family and correlation with disease activity and response to treatment in hairy cell leukemia. Eur J Haematol ,1999, 62: 71-75.
10Steins M B, Bieker R, Padro T, et al, Thalidomide for the treatment of acute myeloid leukemia. Leuk Lymphoma, 2003, 44: 1489-1493.
